Back to Search
RAYMOND PAQUETTE, M.D.
M.D.
Emergency Medical Services (Emergency Medicine) Physician
NPI: 1942200019IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medical Services (Emergency Medicine) PhysicianPrimary
Emergency Medicine — Emergency Medical Services
Code: 207PE0004X
J8707(TX)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Class of 1994
Research & Publications (20)
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
PMID 19652059·J Clin Oncol·2009
3-trial
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
PMID 19295545·Leukemia·2009
8-other
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
PMID 18957672·J Natl Cancer Inst·2008
8-other
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
PMID 18541900·J Clin Oncol·2008
3-trial
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
PMID 18540943·Br J Haematol·2008
3-trial
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
PMID 18477770·Blood·2008
3-trial
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder.
PMID 18299402·J Exp Med·2008
7-preclinical
Systemic mastocytosis with plasma cell dyscrasia: report of a case.
PMID 18061667·Leuk Res·2008
5-case
Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia.
PMID 17915315·Leuk Res·2008
5-case
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
PMID 17710227·J Clin Invest·2007
7-preclinical
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
PMID 17702093·Cancer·2007
8-other
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
PMID 16902153·Blood·2006
3-trial
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
PMID 16775234·N Engl J Med·2006
3-trial
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
PMID 16545730·Biol Blood Marrow Transplant·2006
3-trial
Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment.
PMID 15317732·Blood·2004
8-other
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
PMID 14654525·Clin Cancer Res·2003
3-trial
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.
PMID 12931210·Leukemia·2003
8-other
Diagnosis and management of aplastic anemia and myelodysplastic syndrome.
PMID 12380966·Oncology (Williston Park)·2002
6-review
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
PMID 12204532·Cancer Cell·2002
8-other
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo.
PMID 12145689·Leukemia·2002
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1215 E COURT ST
SEGUIN, TX 78155 - Phone
- (830) 379-2411
Quick Facts
- NPI
- 1942200019
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile